Bruce Car, Ph.D., is a distinguished scientist and the Chief Scientific Officer at BIOHAVEN LTD, a leading biopharmaceutical company focused on developing innovative therapies for neurological and neuropsychiatric disorders. Dr. Car earned his Ph.D. in Neuroscience from Stanford University, where his research focused on the molecular mechanisms underlying neurodegenerative diseases. His academic journey laid a solid foundation for his subsequent career in the biopharmaceutical industry. Prior to joining BIOHAVEN LTD, Dr. Car held several key positions at major pharmaceutical companies, including a significant tenure at Pfizer, where he led research teams in the development of novel treatments for Alzheimer's disease and other neurological conditions. His work at Pfizer was instrumental in advancing several drug candidates into clinical trials. Dr. Car's contributions to the field have been recognized with numerous awards, including the prestigious Neuroscience Research Prize from the American Academy of Neurology. He has also authored over 50 peer-reviewed articles and holds multiple patents related to his research. As Chief Scientific Officer at BIOHAVEN LTD, Dr. Car oversees the company's research and development efforts, guiding the strategic direction of its scientific initiatives. His leadership has been pivotal in driving the company's pipeline forward, particularly in the development of groundbreaking treatments for migraine and rare neurological disorders. Under his guidance, BIOHAVEN LTD has achieved several significant milestones, including the successful launch of new therapies and the establishment of collaborations with leading academic institutions. Dr. Car's vision and expertise continue to be invaluable assets to BIOHAVEN LTD as it strives to improve the lives of patients worldwide.